Recent evidence suggests the presence of opioid dysregulation in autis
tic disorders. The utility of naltexone therapy is summarized and prel
iminary evidence for abnormal plama carboxy-terminal beta-endorphin, A
VP, ACTH, NE & 5-HT levels as markers of the disorder.